Video
Dr. Lerner on OLYMPUS Jelmyto trial: “We've learned a lot of lessons”
Author(s):
“The message is to please consider kidney preservation for these patients with TA low-grade disease,” says Seth P. Lerner, MD.
Video Player is loading.
In this video, Seth P. Lerner, MD, discusses why the findings of the OLYMPUS trial will change the way that clinicians treat patients with upper tract urothelial carcinoma. Lerner is a professor in the Scott Department of Urology and Beth and Dave Swalm Chair in urologic oncology at the Baylor College of Medicine Medical Center in Houston, Texas.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Justin Dubin, MD, on the role for AI in patient education
Considerations for pre-procedure urinalysis, periprocedural antibiotics for onabotA
TMT for bladder cancer: Balancing cost and quality of life
Anne Schuckman, MD, outlines current challenges in NMIBC care
Justin Dubin, MD, on the use of AI in the male infertility space
Bilal Chughtai, MD, discusses pivotal trial of the Butterfly device for BPH
Investigators compare trimodal therapy vs cystectomy in MIBC
Investigators assess ctDNA’s role in NMIBC
RX Review: Implementing mitomycin for LG-IR-NMIBC in clinical practice
RX Review: TURBT vs chemoablation for low-grade, intermediate-risk NMIBC
Related Content
